CARSGEN-B Rises 4.4% as Anticipated Loss for 2025 Set to Decrease by 85%
Stock Performance: CARSGEN-B (02171.HK) opened 4.43% higher at $16.5 with a pre-market trading volume of 10,500 shares, amounting to $173,200.
Financial Outlook: The company expects a net loss of no more than approximately RMB120 million for the year ending December 31, 2025, a significant reduction of at least 85% from RMB798 million in 2024.
Adjusted Loss: The adjusted net loss is anticipated to be around RMB95 million, compared to RMB789 million for the same period in 2024.
Short Selling Activity: The short selling for CARSGEN-B is reported at $1.89 million, with a ratio of 12.440%.
Trade with 70% Backtested Accuracy
Analyst Views on 02171
No data
About the author
CARSGEN-B Rises 4.4% as Anticipated Loss for 2025 Set to Decrease by 85%
Stock Performance: CARSGEN-B (02171.HK) opened 4.43% higher at $16.5 with a pre-market trading volume of 10,500 shares, amounting to $173,200.
Financial Outlook: The company expects a net loss of no more than approximately RMB120 million for the year ending December 31, 2025, a significant reduction of at least 85% from RMB798 million in 2024.
Adjusted Loss: The adjusted net loss is anticipated to be around RMB95 million, compared to RMB789 million for the same period in 2024.
Short Selling Activity: The short selling for CARSGEN-B is reported at $1.89 million, with a ratio of 12.440%.
<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)
UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.
Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.
Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.
Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.
CARSGEN-B Rises 4.4% as Anticipated Loss for 2025 Set to Decrease by 85%
Stock Performance: CARSGEN-B (02171.HK) opened 4.43% higher at $16.5 with a pre-market trading volume of 10,500 shares, amounting to $173,200.
Financial Outlook: The company expects a net loss of no more than approximately RMB120 million for the year ending December 31, 2025, a significant reduction of at least 85% from RMB798 million in 2024.
Adjusted Loss: The adjusted net loss is anticipated to be around RMB95 million, compared to RMB789 million for the same period in 2024.
Short Selling Activity: The short selling for CARSGEN-B is reported at $1.89 million, with a ratio of 12.440%.
<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)
UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.
Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.
Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.
Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.
